Results 91 to 100 of about 7,681 (165)

Preparation and Activities of Macromolecule Conjugates of the CCR5 Antagonist Maraviroc

, 2016
CCR5 antagonists are among the most advanced approaches in HIV therapy and may also be relevant to treatment of graft-versus-host disease and Staphylococcus aureus infection.
Julia Gavrilyuk (1396897), Shigehiro Asano (1331397), Carlos F. Barbas (19478), Dennis R. Burton (1846123)   +3 more
core   +1 more source

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029 [PDF]

, 2015
We characterized maraviroc susceptibility of dual/mixed tropic viruses from subjects enrolled onto phase IIb study A4001029. Maraviroc baseline plasma samples from 13 multidrugexperienced subjects were sequenced and the HIV-1-env gene cloned into ...
Valdez, H, Ceccherini-Silberstein, Francesca, V. Svicher, Harrigan, R., Artese, A., D. Chapman, J. Martinez-Picado, Lewis, M, Balestra E, Clotet, Bonaventura, B. Clotet, Costa G, ALTERI, CLAUDIA, Svicher V, C. Alteri, Alteri C, Martinez Picado J, S. Alcaro, Chapman, D., Swenson, L., Puertas, M.C., Costa, G., Ceccherini Silberstein F., Alcaro, S., Swenson, L, Artese A, BALESTRA, EMANUELA, Saccomandi, P., Ceccherini-Silberstein, F, Clotet, B., M. Surdo, E. Balestra, Martinez Picado, J, Clotet, B, Ceccherini-Silberstein, F., Lewis M, ARTESE, ANNA, G. Costa, SACCOMANDI, PATRIZIA, Artese, A, Saccomandi, P, Costa, G, Svicher, V, Martinez-Picado, J., Chapman, D, Alteri, C., H. Valdez, Clotet B, Parrotta, L, Balestra, E., Balestra, E, Perno CF, Alteri, C, L. Swenson, Parrotta L, A. Artese, Saccomandi P, Surdo, M., Svicher, V., P. Saccomandi, Surdo, M, Ceccherini-Silberstein F, Puertas, MC, F. Ceccherini-Silberstein, M.C. Puertas, AQUARO, STEFANO, Perno, Cf, Alcaro S, Perno, C.F., PERNO, CARLO FEDERICO, Parrotta, L., Martinez Picado, Francisco Javier, S. Aquaro, Harrigan, R, Aquaro, S, M. Lewis, Lewis, M., Alcaro, S, CECCHERINI SILBERSTEIN, FRANCESCA, Swenson L, Martinez-Picado J, L. Parrotta, Chapman D, Surdo M, SVICHER, VALENTINA, Aquaro, S., Aquaro S, Martinez-Picado, J, C.F. Perno, Puertas MC, R. Harrigan, Valdez H, Harrigan R, Valdez, H.   +93 more
core   +1 more source

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

PLoS ONE, 2014
ObjectivesRegimens sparing RATE (ritonavir, abacavir, tenofovir, efavirienz) agents might have better long-term safety. We conducted a feasibility exercise to assess the potential for a randomised trial evaluating RATE-sparing regimens ...
Amit C Achhra, Mark A Boyd, Matthew G Law, Gail V Matthews, Anthony D Kelleher, David A Cooper   +5 more
doaj   +1 more source

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects - Fig 3

, 2019
Steady-state geometric mean Maraviroc concentration-time profile (log-scale) for subjects receiving Maraviroc alone (squares and solid line) and Maraviroc plus Rifabutin (circles and dashed line)(A). Steady-state maraviroc concentration-time profile (log-
E. Sabri (7542692), C. la Porte (7542683), G. Zhang (808141), M. Ghannad (7542677), R. Mallick (5874875), M. Dennehy (7542680), S. Kanji (3407216), D. W. Cameron (7542695), I. Seguin (7542686), D. Tardiff (7542689)   +9 more
core   +1 more source

PREPARATION AND EVALUATION OF MARAVIROC MUCOADHESIVE MICROSPHERES FOR GASTRO RETENTIVE DRUG DELIVERY [PDF]

, 2015
Objective: The objective of this research was to formulate and evaluate pectin and HPMC different grades mucoadhesive microspheres in combination with sodium alginate for controlled release of maraviroc.Methods: The maraviroc mucoadhesive microspheres ...
Ali, Mohamed Ashraf, Velmurugan, Sellappan   +1 more
core   +1 more source

Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?

, 2017
Background Despite the recent advances in the understanding of natalizumab (NTZ) related progressive multifocal leukoencephalopathy (PML) and its associated immune reconstitution inflammatory syndrome (PML-IRIS), the therapeutic options are still under ...
Alessandra Lugaresi, Capobianco M., Gerevini, Simonetta, Simonetta Gerevini, Capra R., Ruggero Capra, Lucia Moiola, Mancinelli, Chiara R., Cristina Scarpazza, Imberti, Luisa, Lugaresi A., Naldi P., Scarpazza C., Paola Naldi, Luca Prosperini, Prosperini L., Moiola, Lucia, Prosperini, Luca, Naldi, Paola, Gerevini S., Mancinelli C. R., De Rossi, Nicola, Chiara R. Mancinelli, Nicola De Rossi, Capobianco, Marco, Moiola L., De Rossi N., Marco Capobianco, LUGARESI, ALESSANDRA, Capra, Ruggero, Scarpazza, Cristina, Imberti L., Luisa Imberti   +32 more
core   +1 more source

Maraviroc susceptibility of parental and site-directed mutagenesis Env clones.

, 2018
Maraviroc susceptibility of parental and site-directed mutagenesis Env clones.
Charles Craig (52348), Wei Huang (36889), Mike Westby (2238055), Paul Simpson (528063), David L. Robertson (64202), Marilyn Lewis (199665), Jonathan Toma (6157130), Mike Mosley (6157133), Julie Mori (3389570), Roy Mansfield (6157136), Elna van der Ryst (6157139), Jeannette M. Whitcomb (161996)   +11 more
core   +1 more source

Computational investigations of potential inhibitors of monkeypox virus envelope protein E8 through molecular docking and molecular dynamics simulations

Scientific Reports
The World Health Organization (WHO) has declared the monkeypox outbreak a public health emergency, as there is no specific therapeutics for monkeypox virus (MPXV) disease. This study focused on docking various commercial drugs and plant-derived compounds
Rohit Das, Anil Bhattarai, Rohit Karn, Buddhiman Tamang   +3 more
doaj   +1 more source

Blocking CCR5 activity by maraviroc augmentation in post-stroke depression: a proof-of-concept clinical trial

BMC Neurology
Background Post-stroke depression (PSD) is a significant impediment to successful rehabilitation and recovery after a stroke. Current therapeutic options are limited, leaving an unmet demand for specific and effective therapeutic options.
Oren Tene, Jeremy Molad, Ofer Rotschild, Aviva Alpernas, Muhamad Hawwari, Estelle Seyman, Nir Giladi, Hen Hallevi, Einor Ben Assayag   +8 more
doaj   +1 more source

Oral Presentation

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source